|| List of recent Factor-related patents
|System, computer-implemented method, and non-transitory, computer-readable medium to determine relative market value of a sale group of livestock based on genetic merit and other non-genetic factors|
Systems, computer-readable medium having computer program, and related computer implemented methods are provided to determine the relative market value of a sale group and to generate a genetic merit scorecard. Such systems, computer-readable medium having computer program, and related computer implemented methods utilize the genetic merit estimates of relatives of a sale group, along with associated economic weighting factors to determine the relative market value of the sale group.
Leachman Cattle Of Colorado, Llc
|Fraud analysis for a location aware transaction|
Fraud analysis for a location aware transaction is disclosed. Location information can be associated with historical fraud events.
At&t Mobility Ii Llc
|Systems, methods and computer program products for determining a consolidated disease risk score from risk factors and a level of composite risk|
Methods, systems and computer program products for assessing a consolidated risk score from two or more risk factors and two or more risk scores are provided. The risk scores include condition-specific composite risk scores based on one or more of the risk factors.
|Highly portable media device|
An improved portable media device and methods for operating a media device are disclosed. According to one aspect, the portable media device can also function as a solid-state drive for data storage.
|Integrated cooling system for electronics testing apparatus|
Example features or aspects of the present invention are described in relation to a small, quiet integrated cooling system for an apparatus for testing electronic devices. Characteristics of the test apparatus including a low noise output, low power consumption and a compact size with a small spatial and volume footprint are selected for deployment and use in a an office like environment.
|Tnt based diagnosis of paroxysmal atrial fibrillation|
The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac troponin, nt-probnp (n-terminal prohormone of brain natriuretic peptide), hscrp, il-6 (interleukin-6) and igfbp7 (insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts).
Roche Diagnostics Operations, Inc.
|Down-regulation of bzip transcription factor genes for improved plant performance|
Methods for modulating plants using optimized zmbzip down-regulation constructs are disclosed. Also disclosed are nucleotide sequences, constructs, vectors, and modified plant cells, as well as transgenic plants displaying increased seed and/or biomass yield, improved tolerance to abiotic stress such as drought or high plant density, improved nitrogen utilization efficiency, increased ear tissue growth or kernel number..
Pioneer Hi-bred International Inc.
|Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)|
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of insulin receptor substrate 2 (irs2) polynucleotides, in particular, by targeting natural antisense polynucleotides of insulin receptor substrate 2 (irs2) polyneucleotides and transcription factor e3 (tfe3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of irs2..
|Process for purifying growth factors from milk and products thereof|
The invention provides process for purifying rnases and growth factors from milk or lactoferrin, the process comprising subjecting the milk or lactoferrin to filtration to separate it into a retentate fraction comprising lactoferrin and a permeate fraction comprising growth factors and/or rnases, wherein prior to and/or during filtration the milk or lactoferrin is subjected to salt treatment such that growth factors and/or rnases flow into the permeate. The invention also provides rnases and growth factors obtained from the process of the invention..
Murray Goulburn Co-operative Co. Ltd.
|Combination treatment of cancer|
The present invention provides mt4-mmp inhibitor and egfr inhibitor for use in the treatment of cancer, wherein said mt4-mmp inhibitor and egfr inhibitor are different from each other. Mt4-mmp (mmp-17) is a glycosylphosphatidyl inositol (gpi) anchored mmp produced by cancer cells that promotes tumor vascularization and metastases.
UniversitÉ De LiÈge
Modulation of activity of neurotrophins
The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (ngf), brain derived neurotrophic factor (bdnf), neurotrophin-3, and neurotrophin-4 (nt-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the vps10p-domain receptor family or modulating the expression of a receptor of the vps10p-domain receptor family.
H Lundbeck A/s
Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
The present invention relates to amino acid sequences and nanobodies that are directed against epidermal growth factor receptor 2 (her2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.. .
Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble fibroblast growth factor receptor 1 (fgfr1) fusion protein such as an extracellular domain of an fgfr1 polypeptide linked to an fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight.
Five Prime Therapeutics, Inc.
Neurotherapeutic nanoparticle compositions and devices
There are provided compositions and methods for treatment of neurodegeneative diseases and cns injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (lif); xav939 and/or one or more of : brain-derived neurotrophic factor (bdnf) or an agonist thereof; epidermal growth factor (egf) or an agonist thereof; glial cell-derived neurotrophic factor (gdnf) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (ctnf) or an agonist thereof; and wnt5a.
Epitopes of epidermal growth factor receptor surface antigen and use thereof
The present invention relates to epitopes of the epidermal growth factor receptor (egfr) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (egf).
Green Cross Corporation
Pharmaceutical composition for treating a metabolic syndrome
The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Lithium stimulation of cord blood stem cell proliferation and growth factor production
The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation.
Rutgers, The State University Of New Jersey
Combination therapies using hdac inhibitors
The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (hdac) inhibitor, such as pxd-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (egfr) inhibitor, such as tarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.. .
Mesenchymal stem cell extract and its use
A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (bmp-7), stromal cell-derived factor-1 (sdf-1), vascular endothelial growth factor (vegf), c-x-c chemokine receptor type-4 (cxcr4), brain-derived neurotrophic factor (bdnf), and/or interleukin-17 (il-17), and wherein the extract is especially suitable for repairing skin aging.. .
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Target tracking intelligent tracking high speed dome camera
Disclosed is a target tracking method for an intelligent tracking high speed dome, comprising: in the process of target tracking, when the position coordinates of a newly selected target in the acquired tracking image are received, matching the position coordinates of the newly selected target in the tracking image, using the target corresponding to the position coordinates of the newly selected target in the tracking image as a current target, and extracting the characteristics of the current target; tracking the current target according to the characteristics thereof, and updating in real time the position coordinates of the current target in the tracking image; converting the updated position coordinates of the current target into speed dome identifiable horizontal rotation value p, vertical rotation value t and magnification factor value z; adjusting in real time the magnification factor of the speed dome according to the value z, and controlling in real time the rotation of the speed dome according to the value p and the value z. When a plurality of the targets appear in a specific scene, the present invention can lock a concerned target and track the target selectively, thus solving the previous problem of tracking an unconcerned target; furthermore, the method of the present invention can reselect and track a target by locking the target manually, thus solving the problem of losing the target..
Hangzhou Hikvision Digital Technology Co., Ltd.
In-cylinder pressure detection device for internal combustion engine
This invention determines whether or not an internal combustion engine is not performing combustion. If the determined result is that the internal combustion engine is not performing combustion, a maximum in-cylinder pressure pmax during motoring is identified by an in-cylinder pressure sensor, and a crank angle θpmax corresponding to the maximum in-cylinder pressure pmax is detected by a crank angle sensor.
Fujitsu Ten Limited
System and a handheld current profiler
A handheld current profiler (hcp) system and method for wading discharge measurement is disclosed. The disclosed hcp has dual capabilities.
Teledyne Rd Instruments, Inc.
Internal combustion engine control apparatus and control method thereof
It is an object of the present invention to improve estimation accuracy of an air excess ratio within a fuel spray and quickly cause the air excess ratio to approximate to a target value when the engine load factor rises. An internal combustion engine control apparatus includes a parameter acquiring section to acquire an air intake parameter and a fuel parameter, a first estimation section to estimate an in-fuel-spray air excess ratio using the air intake parameter and fuel parameter, and a pressure calculation section to calculate, if the in-fuel-spray air excess ratio is less than a target in-fuel-spray air excess ratio, a necessary fuel injection pressure to match the in-fuel-spray air excess ratio with the target in-fuel-spray air excess ratio, in which if the necessary fuel injection pressure is equal to or less than a maximum injection pressure, fuel injection is to be performed at the necessary fuel injection pressure..
Mitsubishi Heavy Industries, Ltd.
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
The present invention relates to antisense of oligonucleotides that modulate the expression of and/or function of fibroblast growth factor 21 (fgf21), in particular, by targeting natural antisense polynucleotides of fibroblast growth factor 21 (fgf21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of fgf21..
Selective reactivation of genes on the inactive x chromosome
Methods and compositions for selectively reactivating genes on the inactive x chromosome (xi) in a locus-specific manner, e.g., genes associated with x-linked diseases, e.g., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females.. .
The General Hospital Corporation
Factor vii conjugates
The present invention relates to the conjugation of factor vii polypeptides with heparosan polymers. The resultant conjugates may be used to deliver factor vii, for example in the treatment or prevention of bleeding disorder.
Novo Nordisk A/s
Coagulation factor ix conjugates
The present invention relates to factor ix polypeptides conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia b..
Novo Nordisk A/s
In vitro pancreatic differentiation of pluripotent mammalian cells
This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (de) medium comprising a tgfp ligand, fibroblast growth factor (fgf), bone morphogenetic protein (bmp), a pi3k inhibitor and optionally a gsk3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; fgf; retinoic acid; and a bmp inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising fgf, retinoic acid, a bmp inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising fgf. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells.
Cambridge Enterprise Limited
Method of obtaining chicken embryonic stem cells
The present invention concerns a method of culturing embryonic stem (es) cells of avian, comprising the steps of: a) suspending es cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (igf-1) and ciliary neurotrophic factor (cntf); and animal serum; and optionally, at least one growth factors selected in the group comprising interleukin 6 (ii-6), interleukin 6 receptor (ii-6r), stem cell factor (scf), fibroblast growth factor (fgf), leukaemia inhibitory factor (lif), interleukin 11 (ii-11), oncostatin and cardiotrophin; b) seeding the suspension of es cells obtained in step a) on a layer of feeder cells and further culturing the es cells for at least between 2 to 10 passages; c) optionally removing at least one growth factors selected scf, fgf, ii-6, ii-6r, lif, oncostatin and cardiotrophin and ii-11 from the culture medium; d) further culturing the es cells in the medium of step c) on a layer of feeder cells.. .
Methods for producing recombinant factor viii chains from non-filamentous fungi, their functional reconstitution and applications thereof
A process of producing heavy chain peptide and/or light chain peptide of recombinant factor viii protein includes using the pichia pastoris expression system. A process of producing a functional recombinant factor viii protein by reconstituting the heavy chain and light chain produced using said pichia pastoris expression system.
Christian Medical College
Therapeutic compounds and compositions
The present invention provides compounds and compositions that inhibit factor xia or kallikrein and methods of using these compounds and composition.. .
Exithera Pharmaceuticals Inc.
Factor viii conjugates
The present invention relates to fviii conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia..
Novo Nordisk A/s
Method of preparing a growth factor concentrate derived from human platelets
The invention relates to a method of preparing an intra-dermally, intra-articularly, sub-dermally or topically administrable growth factor concentrate derived from human platelets. The method comprises the steps of suspending human platelets in multiple electrolyte isotonic solution; snap-freezing the suspension; thawing the frozen suspension; and sterile-filtering the suspension.
Kasiak Research Pvt. Ltd.
Use of kgf in the treatment of menopausal disorders
The present invention relates to the use of keratinocyte growth factor (kgf/fgf7) and pharmaceutical compositions thereof in the treatment of vaginal atrophy, dysuria, vaginal pain and/or vaginal dryness induced by a post-menopausal state, by surgical intervention, by illness and/or by chemotherapy or radiotherapy treatments.. .
Università Degli Studi Di Roma "la Sapienza"
Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment
The invention refers to a composition standardized in heterologous embryo-peptides, used as a dietary supplement and to a process for its obtainment. The composition consists of heterologous embryonic extract, standardized in embryo-peptides, maltodextrin, selenium yeast, chromium yeast, zinc chelated in embryo-peptides, pyridoxine, mixture of cationic peptides, formed by enzymatic hydrolysis of vitellus and egg white remaining after chicken embryo harvesting, with antitrypsin and endocytosis promoting activity, sodium taurocholate, expanded silicon dioxide, magnesium stearate, methylparaben and propylparaben.
Sc Hipocrate 2002 Serv Srl
Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
A formulation for treating omega-3 fatty acid deficiency is disclosed containing about 90% or more omega 3 fatty acids by weight comprised of a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. Epa+dha are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition.
Pivotal Therapeutics, Inc.
The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of vegf, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization..
Opko Pharmaceuticals, Llc
Ligands for odor receptors and olfactory neurons
The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules..
The Regents Of The University Of California
Communication module having a rotatable connector assembly for multiple connection orientations
An optical communication module include a housing having a circuit element configured to provide an optical communication function, and a rotatable connector assembly coupled to the housing, the rotatable connector assembly configured to rotate between a first position and a second position, wherein when in the first position, the rotatable connector assembly allows the communication module to interface with a first form factor card cage and when in the second position, the rotatable connector assembly allows the communication module to interface with a second form factor card cage.. .
Wirelessly charged battery system
The disclosure features power transmitting apparatus for wireless power transfer to a receiver that includes a housing having a form factor that corresponds to a container featuring lateral surfaces, a bottom surface, and an opening opposite the bottom surface, a first coil formed by a continuous path of electrically conductive material and featuring a plurality of non-planar loops that conform to a first pair of opposite lateral surfaces and to the bottom surface, and a second coil formed by a continuous path of electrically conductive material and featuring a plurality of non-planar loops that conform to a second pair of opposite lateral surfaces and to the bottom surface.. .
Carbon fiber-based chassis components for portable information handling systems
A chassis component of an information handling system may include a chassis main lid component constructed of carbon fiber composite material that supports a lid chassis antenna housing that includes an internal antenna cavity defined therein to create an antenna window for the system. The carbon fiber composite material may be attached to the chassis antenna housing by an interlocking rib that provides sufficient joint strength to allow for a substantially larger and extended chassis antenna housing with larger antenna window that may be spaced further away from the carbon fiber composite material of the chassis main lid component than would otherwise be possible for the same form factor size so as to minimize or substantially eliminate shielding or blocking of wireless signals by the carbon fiber composite material lid component that would result in reduced system wireless performance..
System and providing crowd sourcing platform for task allocation
The present subject matter discloses a system and a method for allocating task on crowdsourcing platform. A task may be received from a first user on the platform.
Tata Consultancy Services Limited
Computerized determining hospital admission risk
A computing device may compute the hospital admission risk of a patient as of a first risk calculation date after provision of one or more interventions for the patient. Each such intervention may be of a type that can readily be provided without bringing the patient to a hospital.
Systems and methods for determining secondary hyperparathyroidism risk factors
A computer-implemented method for determining at least one secondary hyperparathyroidism risk factor (“shpt”) for a patient is implemented using a risk evaluation computer system in communication with a memory. The method includes receiving a plurality of demographic data associated with a patient from a mobile computing device, receiving a concentration of a renal filtration marker associated with the patient from the mobile computing device, and determining at least one shpt risk factor for the patient based on the plurality of demographic data and the concentration of the renal filtration marker using at least one estimating equation, the shpt risk factor indicating a likelihood that the patient has shpt..
Processing of page-image based document to generate a re-targeted document for different display devices which support different types of user input methods
Method and system for processing a page-image based input document such as pdf and generate output documents, in a page-image based format or another format, which have a different layout than the original document. Certain contents in the original document removed and other contents are reorganized in this process.
Konica Minolta Laboratory U.s.a., Inc.
Small form factor field installable outside plant connector housing
A connector housing apparatus for allowing field engineers or technicians to run cable point to point, and to protect the connection in an environmentally sealed, crush resistant housing is provided. The connector housing apparatus includes a connector housing body, two sealing boots, two sealing elements, two seal nuts, a fiber optic adapter, a fiber optic adapter insert that holds the fiber optic adapter and two fiber optic pigtails connected to two fiber optic cables.
Afl Telecommunications Llc
Methods and kits for measuring von willebrand factor
Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having at least two of a g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
Bloodcenter Research Foundation
Diagnostic kit for igfbp-4 proteolytic fragments in a patient sample
The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting igfbp-4 (insulin-like growth factor binding protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of igfbp-4 are also disclosed..
Method for producing ethanol from biomass
Provided is a method for efficiently producing ethanol by ethanol fermentation from xylose using a saccharified biomass, which contains various fermentation inhibitors. A method for producing ethanol from biomass of the present invention includes the step of culturing a xylose-utilizing yeast transformed so as to overexpress a gene for an acetic acid -responsive transcription factor in combination with a saccharified biomass..
National University Corporation Kobe University
Sucrose transporter genes for increasing plant seed lipids
This invention relates to polynucleotide sequences encoding sut2 or sut4 sucrose transporter genes. Methods for increasing seed oil content and evaluating increased oil content in a plant seed are described.
E I Du Pont De Nemours And Company
Manufacture of vascular smooth muscle cells and the use
A method for preparing brain-specific vascular smooth muscle cells comprising the step of: (a) contacting a population of stem cells with a composition comprising a bone morphogenetic protein (bmp) antagonist, a fibroblast growth factor (fgf) and an activin or nodal inhibitor to produce a population of neural crest cells.. .
Agency For Science, Technology And Research
Inhibitors of the epidermal growth factor receptor- heat shock protein 90 binding interaction
Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (egfr) and a heat shock protein 90 (hsp90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog.
The Regents Of The University Of Michigan
Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.. .
Vegenics Pty Limited
Antigen peptide originated from t790m point-mutated sequence of epidermal growth factor receptor
The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having t790m point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.. .
Kanagawa Prefectural Hospital Organization
Compositions of protein receptor tyrosine kinase inhibitors
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, tropomysosin related kinases (trk), in particular the nerve growth factor (ngf) receptor, trka. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of ngf receptor trka..
Vm Pharma Llc